Ligand Pharmaceuticals Inc
LGND133.750USD
+1.030+0.78%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
2.58BCap. mercado
PérdidaP/E TTM
Más Datos de Ligand Pharmaceuticals Inc Compañía
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.
Información de la empresa
Símbolo de cotizaciónLGND
Nombre de la empresaLigand Pharmaceuticals Inc
Fecha de salida a bolsaNov 18, 1992
Director ejecutivoMr. Todd C. Davis
Número de empleados68
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 18
Dirección555 Heritage Drive, Suite 200
CiudadJUPITER
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal33458
Teléfono18585507500
Sitio Webhttps://www.ligand.com/
Símbolo de cotizaciónLGND
Fecha de salida a bolsaNov 18, 1992
Director ejecutivoMr. Todd C. Davis
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jason M. Aryeh
Mr. Jason M. Aryeh
Independent Director
Independent Director
137.16K
+0.89%
Dr. John W. Kozarich ,Ph.D.
Dr. John W. Kozarich ,Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
45.30K
-2.02%
Dr. Stephen L. Sabba, M.D.
Dr. Stephen L. Sabba, M.D.
Independent Director
Independent Director
35.05K
+3.57%
Dr. John L. Lamattina, Ph.D.
Dr. John L. Lamattina, Ph.D.
Independent Director
Independent Director
31.98K
+3.93%
Mr. Andrew Reardon
Mr. Andrew Reardon
Chief Legal Officer
Chief Legal Officer
17.05K
-4.31%
Mr. Octavio (Tavo) Espinoza
Mr. Octavio (Tavo) Espinoza
Chief Financial Officer
Chief Financial Officer
10.12K
+2.26%
Dr. Nancy Ryan Gray, Ph.D.
Dr. Nancy Ryan Gray, Ph.D.
Independent Director
Independent Director
9.35K
+14.86%
Mr. Jason Haas
Mr. Jason Haas
Independent Director
Independent Director
6.86K
+21.40%
Dr. Martine Zimmermann, Pharm.D.
Dr. Martine Zimmermann, Pharm.D.
Independent Director
Independent Director
4.29K
+31.26%
Mr. Todd C. Davis
Mr. Todd C. Davis
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jason M. Aryeh
Mr. Jason M. Aryeh
Independent Director
Independent Director
137.16K
+0.89%
Dr. John W. Kozarich ,Ph.D.
Dr. John W. Kozarich ,Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
45.30K
-2.02%
Dr. Stephen L. Sabba, M.D.
Dr. Stephen L. Sabba, M.D.
Independent Director
Independent Director
35.05K
+3.57%
Dr. John L. Lamattina, Ph.D.
Dr. John L. Lamattina, Ph.D.
Independent Director
Independent Director
31.98K
+3.93%
Mr. Andrew Reardon
Mr. Andrew Reardon
Chief Legal Officer
Chief Legal Officer
17.05K
-4.31%
Mr. Octavio (Tavo) Espinoza
Mr. Octavio (Tavo) Espinoza
Chief Financial Officer
Chief Financial Officer
10.12K
+2.26%
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Captisol
13.46M
29.69%
Qarziba
5.44M
12.00%
Filspari
5.30M
11.69%
Kyprolis
4.72M
10.42%
Milestone
4.38M
9.67%
Other
12.02M
26.52%
Sin datos
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Captisol
13.46M
29.69%
Qarziba
5.44M
12.00%
Filspari
5.30M
11.69%
Kyprolis
4.72M
10.42%
Milestone
4.38M
9.67%
Other
12.02M
26.52%
Estadísticas de accionistas
Actualizado: vie., 16 de may
Actualizado: vie., 16 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
13.86%
The Vanguard Group, Inc.
10.63%
Janus Henderson Investors
5.33%
Macquarie Investment Management
4.70%
Dimensional Fund Advisors, L.P.
3.86%
Other
61.62%
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
13.86%
The Vanguard Group, Inc.
10.63%
Janus Henderson Investors
5.33%
Macquarie Investment Management
4.70%
Dimensional Fund Advisors, L.P.
3.86%
Other
61.62%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
57.94%
Investment Advisor/Hedge Fund
37.89%
Individual Investor
2.39%
Research Firm
1.84%
Pension Fund
1.60%
Bank and Trust
0.41%
Sovereign Wealth Fund
0.28%
Hedge Fund
0.05%
Insurance Company
0.03%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
534
19.71M
102.14%
-793.05K
2025Q1
554
19.82M
102.82%
-711.89K
2024Q4
546
19.28M
100.16%
-1.51M
2024Q3
543
19.17M
104.83%
-583.22K
2024Q2
527
18.31M
101.74%
-865.78K
2024Q1
520
17.60M
99.35%
-393.03K
2023Q4
527
16.97M
97.29%
-861.76K
2023Q3
515
17.24M
99.38%
-910.17K
2023Q2
526
17.09M
98.94%
-1.02M
2023Q1
528
16.47M
96.50%
-1.33M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
BlackRock Institutional Trust Company, N.A.
2.67M
13.86%
-26.33K
-0.97%
Mar 31, 2025
The Vanguard Group, Inc.
2.05M
10.63%
-29.89K
-1.44%
Mar 31, 2025
Janus Henderson Investors
1.03M
5.33%
+12.53K
+1.23%
Mar 31, 2025
Macquarie Investment Management
906.23K
4.7%
+21.85K
+2.47%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
744.93K
3.86%
+21.91K
+3.03%
Mar 31, 2025
State Street Global Advisors (US)
727.13K
3.77%
-16.51K
-2.22%
Mar 31, 2025
Congress Asset Management Company, LLP
642.71K
3.33%
+21.23K
+3.42%
Mar 31, 2025
Stephens Investment Management Group, LLC
607.22K
3.15%
-5.56K
-0.91%
Mar 31, 2025
Chicago Capital, LLC
554.52K
2.87%
+2.93K
+0.53%
Mar 31, 2025
Geode Capital Management, L.L.C.
464.45K
2.41%
+26.01K
+5.93%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Invesco Pharmaceuticals ETF
3.03%
Virtus LifeSci Biotech Products ETF
1.91%
SPDR S&P Pharmaceuticals ETF
1.86%
Franklin Genomic Advancements ETF
1.68%
Invesco S&P SmallCap Health Care ETF
1.57%
Pacer US Small Cap Cash Cows Growth Leaders ETF
1.34%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.32%
iShares U.S. Pharmaceuticals ETF
1.1%
First Trust Multi-Manager Small Cap Opportunities ETF
0.71%
Simplify Health Care ETF
0.52%
Ver más
Invesco Pharmaceuticals ETF
Proporción3.03%
Virtus LifeSci Biotech Products ETF
Proporción1.91%
SPDR S&P Pharmaceuticals ETF
Proporción1.86%
Franklin Genomic Advancements ETF
Proporción1.68%
Invesco S&P SmallCap Health Care ETF
Proporción1.57%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Proporción1.34%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporción1.32%
iShares U.S. Pharmaceuticals ETF
Proporción1.1%
First Trust Multi-Manager Small Cap Opportunities ETF
Proporción0.71%
Simplify Health Care ETF
Proporción0.52%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
